94 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
and secondary endpoints of safety/tolerability and pharmacokinetics. There were no dose-limiting toxicities or other safety signals. Potentially
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
and programs
CEO succession planning
DE&I initiatives
Recruitment and retention of talent
Workplace culture
Workplace health, safety and well
8-K
EX-99.1
981b0
1 Mar 24
Regulation FD Disclosure
9:16am
8-K
EX-99.1
ew59yld7 wbb8cevtc2z
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
8-K
EX-99.1
v69h51ypzbmvalx
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am
8-K
EX-99.1
s4bx s9fu
9 Nov 22
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
8:15am
8-K
EX-99.1
465l8x5f49g
4 Oct 22
Regulation FD Disclosure
5:03pm